A prospective case-control study of 150 participants found circulating cell-free DNA distinguished ovarian cancer from benign ...

Testing to look for circulating tumor DNA in the blood is not new. These liquid biopsies – a fancy way of saying blood tests ...

Dr. Rick Baehner, Abbott’s chief medical officer for precision oncology, spoke to MedTech Dive about how the new version of the Oncodetect test performs and the market it addresses.

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B ...

HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data ...

A retrospective single-center study found that tumor-informed circulating tumor DNA monitoring agreed with radiologic ...

Five-year trial results support chemotherapy de-escalation in HER2-positive breast cancer, with ctDNA offering additional ...

The growing role of Molecular Residual Disease (MRD) testing in cancer diagnosis and monitoring will be the focus of an ...

Beyond MSD and Moderna’s melanoma vaccine, other notable skin cancer data were shared at ESMO 2026.

NeoCOAST-2 trial finds early ctDNA clearance in blood tests linked to improved lung cancer outcomes, potentially guiding ...

New Prostate Cancer Approval Reinforces the Importance of Comprehensive Genomic Testing / cancer, FDA, genomic testing, ...

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support ...